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Abstract
Background: To date, nine Parkinson disease (PD) genome-wide association studies in North American, European
and Asian populations have been published. The majority of studies have confirmed the association of the
previously identified genetic risk factors, SNCA and MAPT, and two studies have identified three new PD
susceptibility loci/genes (PARK16, BST1 and HLA-DRB5). In a recent meta-analysis of datasets from five of the
published PD GWAS an additional 6 novel candidate genes (SYT11, ACMSD, STK39, MCCC1/LAMP3, GAK and
CCDC62/HIP1R) were identified. Collectively the associations identified in these GWAS account for only a small
proportion of the estimated total heritability of PD suggesting that an ‘unknown’ component of the genetic
architecture of PD remains to be identified.
Methods: We applied a GWAS approach to a relatively homogeneous Ashkenazi Jewish (AJ) population from New
York to search for both ‘rare’ and ‘common’ genetic variants that confer risk of PD by examining any SNPs with
allele frequencies exceeding 2%. We have focused on a genetic isolate, the AJ population, as a discovery dataset
since this cohort has a higher sharing of genetic background and historically experienced a significant bottleneck.
We also conducted a replication study using two publicly available datasets from dbGaP. The joint analysis dataset
had a combined sample size of 2,050 cases and 1,836 controls.
Results: We identified the top 57 SNPs showing the strongest evidence of association in the AJ dataset (p < 9.9 ×
10
-5). Six SNPs located within gene regions had positive signals in at least one other independent dbGaP dataset:
LOC100505836 (Chr3p24), LOC153328/SLC25A48 (Chr5q31.1), UNC13B (9p13.3), SLCO3A1(15q26.1), WNT3(17q21.3) and
NSF (17q21.3). We also replicated published associations for the gene regions SNCA (Chr4q21; rs3775442, p = 0.037),
PARK16 (Chr1q32.1; rs823114 (NUCKS1), p = 6.12 × 10
-4), BST1 (Chr4p15; rs12502586, p = 0.027), STK39 (Chr2q24.3;
rs3754775, p = 0.005), and LAMP3 (Chr3; rs12493050, p = 0.005) in addition to the two most common PD
susceptibility genes in the AJ population LRRK2 (Chr12q12; rs34637584, p = 1.56 × 10
-4) and GBA (Chr1q21;
rs2990245, p = 0.015).
Conclusions: We have demonstrated the utility of the AJ dataset in PD candidate gene and SNP discovery both
by replication in dbGaP datasets with a larger sample size and by replicating association of previously identified PD
susceptibility genes. Our GWAS study has identified candidate gene regions for PD that are implicated in neuronal
signalling and the dopamine pathway.
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Genetic linkage studies of Parkinson’s Disease (PD) have
identified susceptibility loci in five genes which include
SNCA [1] (PARK1), Parkin [2] (PARK2), PTEN-induced
putative kinase [3] (PINK1;PARK6), DJ-1 [4] (PARK7)
and Leucine rich repeat kinase 2 [5] (LRRK2; PARK8).
Mutations in these genes are rare and highly penetrant
with large effects (e.g Parkin, PARK2), and their preva-
lence may vary substantially by age at onset (AAO),
family history of PD (FHPD), and ethnicity [6,7]. On the
other hand, common genetic variants defined as variants
with a minimum allele frequency (MAF) of 5% to 20-
30% are also believed to contribute to PD disease sus-
ceptibility. Often genome wide association studies
(GWAS) exclude SNPs with low allele frequencies
(MAF < 5%), thereby excluding some rare variants that
may contribute to disease susceptibility. To date, nine
PD GWAS studies in North American, European and
Asian populations have been published [8-16]. While
the majority of studies have confirmed the association
of the previously identified genetic risk factors, SNCA
and MAPT, only two studies have identified three new
PD susceptibility genes that reached genome wide signif-
icance [13,16]. In a Japanese population, a GWAS iden-
tified the new susceptibility loci PARK16 at chr1q32 and
BST1 on 4p15 and the HLA region was identified as a
susceptibility locus in a late-onset sporadic PD popula-
tion from North America [13,16]. In a recent meta-ana-
lysis of datasets from five of the published PD GWAS
an additional 6 novel candidate genes (SYT11, ACMSD,
STK39, MCCC1/LAMP3, GAK and CCDC62/HIP1R)
were identified [17]. Collectively the associations identi-
fied in these GWAS account for only a small proportion
of the estimated total heritability of PD suggesting that
an ‘unknown’ component of the genetic architecture of
PD remains to be identified. Some of the contributing
factors to the difficulties in identification of risk variants
are: etiologic heterogeneity across populations, other
genetic mechanisms like methylation, and the impor-
tance of multiple, rare variants in common diseases,
which are not well captured by current GWAS
approaches.
To overcome some of these limitations, we applied a
GWAS approach to a relatively homogeneous Ashkenazi
Jewish (AJ) population living in the New York area to
search for both ‘rare’ and ‘common’ genetic variants that
confer risk of PD by examining any SNPs with allele fre-
quencies exceeding 2%. We have focused on a genetic
isolate, the AJ population, as a discovery dataset since
this cohort has a higher sharing of genetic background,
and historically experienced a significant bottleneck,
thereby potentially increasing allele frequencies such
that some rare variants in other European populations
may be more frequent in the AJ population [18-23].
Our study had three main aims. First, we used our AJ
case-control population as a discovery dataset and per-
formed a GWAS using an overall MAF threshold of >
2% to identify novel candidate SNPs, and conducted a
replication study using two publicly available datasets
from dbGaP (CIDR/Pankratz et al 2009 [24] Genome
wide association study in familial PD and NINDS: The
National Institute of Neurological Disorders and Stroke
[11]). Second, we re-analyzed the dbGaP datasets from
CIDR/Pankratz et al 2009 and NINDS using an overall
MAF threshold of 2% or higher to identify rare genetic
variants in these datasets, and attempted to replicate the
findings in the AJ dataset. Third, we examined suscept-
ibility and candidate genes identified in previously pub-
lished GWAS and other association studies, including
MAPT, SNCA, LRRK2, GBA, PARK16, BST1, HLA-DRA,
SYT11, ACMSD, STK39, MCCC1/LAMP3, GAK,a n d
CCDC62/HIP1R in all three datasets. While the sample
size of the AJ discovery set is relatively small, the joint
analysis dataset had a combined sample size of 2,050
cases and 1,836 controls.
Methods
Subjects
The AJ GWAS dataset was created by combining parti-
cipants from two studies the Genetic Epidemiology of
PD study (PD EPI) and the AJ Study. The ascertainment
of cases (n = 168) and controls (n = 84) for the PD EPI
study was described in detail in Marder et al. [25] and
the ascertainment of cases (n = 100) and controls (n =
94) for the AJ study is described below. Briefly, for the
PD EPI and AJ study, PD cases were recruited from the
Center for PD and Other Movement Disorders at
Columbia University. All met research criteria for PD.
All controls underwent the same evaluation as cases,
which included a medical history, Unified Parkinson’s
Disease Rating Scale (UPDRS) and Mini Mental State
Exam (MMSE). Family history of PD and related disor-
ders in first-degree relatives was obtained using a struc-
tured interview that has been shown to be reliable and
valid.
The PD EPI study was enriched for cases with AAO of
50 years of age or younger and the majority of controls
were recruited via random digit dialling. Information on
Jewish ancestry in each of the grandparents was
obtained during an interview. Information about Ashke-
nazi origin was not specifically obtained; however ~90%
of Jews in the United States are Ashkenazi. For the AJ
study, PD cases were recruited specifically based on
their AJ ancestry and information on Ashkenazi Jewish
ancestry in each of the grandparents was obtained dur-
ing an interview. This study was approved by the Insti-
tutional Review Board at Columbia University Medical
Center. Each study participant signed a written informed
Liu et al. BMC Medical Genetics 2011, 12:104
http://www.biomedcentral.com/1471-2350/12/104
Page 2 of 16c o n s e n ta p p r o v e db yt h eU n i v e r s i t yH u m a nE t h i c s
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Genotyping and Quality Control Assessment
A total of 268 cases and 178 controls were genotyped
using the Illumina Human 610-quad bead arrays (Cases
n = 91 and Controls n = 96) or the Illumina Human
660-quad bead arrays (Cases n = 191 and Controls n =
84). All DNAs were derived from whole blood.
Quality scores were determined from allele cluster
definitions for each SNP as determined by the Illumina
GenomeStudio Genotyping Module version 3.0 and the
combined intensity data from 100% of study samples.
Genotype calls with a quality score (Gencall value) of
0.25 or higher were considered acceptable. We geno-
typed 10 samples in duplicate to assess genotyping
accuracy and found blind duplicate reproducibility to
be 100%. In addition, 10 cases and 2 controls were
genotyped by the above 2 platforms, and for the over-
lapping SNPs, genotypes matched. 6 individuals was
removed with similar genotype with others in the IBD
analysis using PLINK http://pngu.mgh.harvard.edu/
~purcell/plink/ [26]. Subsequently, for the samples
with duplicates, we used the Illumina Human 660-
quad bead arrays. Overall we performed additional
quality control (QC) measures using PLINK. We
excluded SNPs with the following characteristics: miss-
ing genotyping rate > 5%; minimum allele frequency <
2%; Hardy-Weinberg Equili b r i u m( H W E )t e s t[ 2 7 ]a ta
p-value < 0.0001 in controls. This screen reduced the
total number of analyzed SNPs by 1.67%. Following all
QC measures, we analyzed 525,124 SNPs. Figure 1a)
represents the Q-Q plot for the AJ dataset. Q-Q plot
was generated using the WGAviewer program [28].
SNAP http://broad.mit.edu/mpg/snap/ was used to
identify and to annotate nearby SNPs in linkage dise-
quilibrium (proxies) based on HapMap, to query and
display LD and regional association plot with GWAS
results [29].
GBA and LRRK2 mutation status have been reported
previously in the AJ sample derived from PD EPI study
previously [22,30]
Population stratification
We examined ancestry for each subject to estimate cryp-
tic population stratification using the identity-by-state
(IBS) based clustering method as implemented in
PLINK [26]. Briefly, we used all available SNPs (n =
522,578 autosomal SNPs) for the PLINK analysis (ver-
sion 1.05) to assess underlying population structure. To
assess potential cryptic population stratification, we aug-
mented the 446 AJ samples with white subjects from
the HapMap website http://www.hapmap.org/, which
included 60 European Americans, 60 Yorubans and 90
Asians. The best fitting model assumed two underlying
populations; however, the proportion of the second clus-
ter was small (n = 14), and this group of individuals
clustered with the HapMap whites. These subjects were
not dropped from the analysis.
Figure 1 Quantile-Quantile plots for test statistics for SNPs
passing quality control in each dataset. Figure shows -log10 (p-
value) of observed association statistics in Y-axis, compared to -log10
(p-value) of the association statistics expected under the null
hypothesis of no association in X-axis. The solid line represents
concordance of observed and expected values. The genomic
inflation factor, l, is shown for each dataset. A) Ashkenazi Jewish (l
= 1.003), b) NINDS (l = 1.026), and c) CIDR/Pankratz et al 2009(l =
1.031).
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We conducted single point allelic association analysis using
the Mantel-Haenszel chi-squared test statistic, which tests
for SNP-disease association conditional on population sub-
cluster estimated from the PLINK analysis described above
(Additional file 1). For the SNPs with the strongest support
for association and are located within a gene, we performed
two additional analyses for the region containing the top
SNPs and for several PD genes that have been previously
reported. First, we conducted haplotype analysis using 2 or
3c o n t i g u o u sS N P sa si m p l e m e n t e di nt h eP L I N Kp r o g r a m .
This approach computed a Wald statistic p value for com-
paring each haplotype between cases and controls as well
as an overall p-value which compares the frequencies
across all the haplotypes [26]. Second, we performed odds
ratios adjusting for age and sex as implemented in PLINK
(Results; Additional files 1 and 2).
Candidate Gene Analyses
We performed separate analyses focusing on SNPs in
the candidate genes that were identified from previous
genome wide association studies, including MAPT,
SNCA, LRRK2, GBA, PARK16, BST1, HLA-DRA, SYT11,
ACMSD, STK39, MCCC1/LAMP3, GAK and CCDC62/
HIP1R. For these genes, we computed Mantel-Haenzel
chi-squared test to assess allelic association and com-
puted odds ratios adjusting for sex and age to assess the
effect size of the SNP in the AJ population.
Replication Datasets
To determine whether the findings from the Ashkenazi
Jewish discovery samples are supported in independent
samples, we examined the publicly available GWAS data
for the CIDR/Pankratz et al 2009 [24] and NINDS PD
GWAS [11]http://www.ncbi.nlm.nih.gov/sites/entrez?
db=gap; Downloaded on September 25th, 2009. NINDS
dataset comprise 931 cases and 798 controls, while the
CIDR/Pankratz et al 2009 dataset comprise 900 cases
and 867 controls. After applying the same QC measures
to these two datasets as those applied to the AJ dataset,
the final datasets included 923 cases and 798 controls
for the NINDS dataset, and 859 cases and 860 controls
for the CIDR/Pankratz et al 2009 dataset. Characteristics
of the two datasets are described in Table 1.
We applied the same allelic association model to the
replication datasets to determine whether the candidate
SNPs from the AJ dataset are associated with PD in
these two unrelated datasets. To assess the overall effect
of candidate SNPs, we then conducted a meta-analysis
using the weighted Z-score meta-analysis as implemen-
ted in METAL (http://www.sph.umich.edu/csg/abecasis/
metal/). For some SNPs, only two of three datasets were
used because the SNPs were not available in all datasets
and imputation was unreliable.
Results and discussion
Table 1 shows the summary characteristics of genotyped
subjects for the AJ discovery dataset and two replication
datasets of white subjects that were comparable in
demographic and clinical characteristics. The AJ dataset
had a slightly larger number of cases (n = 268) versus
controls (n = 178), but the remaining two datasets had a
comparable number of cases versus controls. To control
for population stratification, we excluded subjects who
clustered differently from the majority of Ashkenazi
Jews (See Subsection Population Stratification, Materials
and Methods section for details).
Overall, the NINDS dataset obtained from the dbGaP
consisted of 931 PD cases and 798 controls, a total of
eight PD cases were excluded because these individuals
were missing genotype data from the Human Hap300v1.
The CIDR/Pankratz et al 2009 dataset consisted of 900
cases and 867 controls. We excluded 41 cases and seven
controls with genotyping rates < 99%. These two datasets
were downloaded from the dbGaP site on September 25th,
2009; therefore, the number of cases and controls do not
necessarily agree with the publications for the two studies
[11,24]. For these two external datasets, we did not have
Table 1 Characteristics of the genotyped subjects from the Ashkenazi Jewish, NINDS, and CIDR/Pankratz et al 2009
datasets
Ashkenazi Jews NINDS CIDR/Pankratz et al 2009 Overall
Case Control Case Control Case Control Case Control
Subjects (%) 268(60.1) 178(39.9) 923(53.6) 798(46.4) 859(50.0) 860(50.0) 2050(52.8) 1836(47.2)
Mean age at onset/examination Year ± SD* 59.9 ± 12.1 69.8 ± 8.8 58.5 ± 13.2 58.6 ± 16.4 61.8 ± 10.9 54.8 ± 13.0 60.0 ± 12.2 57.9 ± 14.9
Male(%) 255(57.2) 886(51.5) 850(49.4) 1991(51.2)
Proportion of EOPD
# 24.5% 26.0% 15.0% 21.3%
Total 446 1721 1719 3886
Genotyping rate 99.85 99.79 99.81 99.82
Markers passing QC 525124 517805 334161
* Age at onset for cases and age at examination for controls,
# EOPD: Early Onset of PD, with age at onset younger than or equal to 50
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these three datasets, the proportion of male subjects was
slightly higher in the AJ dataset than in the two other
datasets. The mean age at onset for the affected indivi-
duals in the AJ dataset was 59.9 and was comparable to
the affecteds in the NINDS dataset (58.5 years) and the
CIDR/Pankratz et al 2009 dataset (61.8). The proportion
of early onset PD (defined as onset ≤50 years of age) was
comparable between the AJ- and NINDS datasets (Table
1). The mean age at examination for unaffected individuals
for the AJ dataset was older (69.8 years) than the controls
in the replication datasets (58.6 for the NINDS dataset,
and 54.8 for the CIDR/Pankratz et al 2009 dataset).
Genome Wide and Allelic Association Study Results
AJ dataset
We identified seven candidate SNPs of high priority
from the AJ discovery dataset (Table 2). Specifically,
we identified the top 57 SNPs with P value < 9.9 × 10
-
5 from the AJ discovery dataset (Additional file 1; Fig-
ure 2a). Although these SNPs do not meet the strin-
gent Bonferroni corrected genome wide significance p-
value of 9.5 × 10
-8, these SNPs provide the strongest
support for harbouring susceptibility genes for PD. To
further screen these 57 candidate SNPs, we checked to
see whether they were: (1) located within genic
regions, and (2) replicated in at least one independent
dataset. Twenty-seven out of 57 SNPs were located in
or near to genes (Additional file 1), and the remainder
of SNPs were located in intergenic regions. When we
evaluated those SNPs in the two replication data sets,
we identified six SNPs which were located within six
candidate genes, namely LOC100505836, LOC153328/
SLC25A48, UNC13B, SLCO3A1, WNT3,a n dNSF
(Table 2 Figure 3). Of the six SNPs located within a
gene, for three SNPs (rs10121009, rs7171137, and
rs183211), the direction of allelic association was the
same in all three datasets, whereas for SNPs rs415430,
Table 2 Top Candidate SNPs from the Ashkenazi Jewish, NINDS and CIDR/Pankratz et al 2009 Datasets
Ashkenazi Jewish NINDS CIDR/Pankratz et
al 2009
Meta-analysis
SNP CHR BP A1 GENE F_A P OR F_A P OR F_A P OR A2 Z P Direction
F_U 95%
CI
F_U 95%
CI
F_U 95%
CI
score
rs1694037 3 21941114 T LOC10055836 0.096 1.02 × 10
-5 0.42 0.097 0.849 1.02 0.121 0.049 1.24 T -1.3 0.193 -+ +
0.199 0.29-
0.62
0.095 0.81-
1.28
0.100 1.00-
1.54
rs4976493 5 135210022 A SLC25A48 0.442 6.66 × 10
-5 1.77 0.403 0.026 1.17 0.367 0.190 0.91 A 2.8 0.005 ++-
0.309 1.34-
2.35
0.366 1.02-
1.34
0.389 0.79-
1.05
rs10121009 9 35259819 A UNC13B 0.131 5.32 × 10
-5 0.49 0.182 0.045 0.84 0.185 0.032 0.83 A -4.7 2.75
×
10
-6
---
0.235 0.34-
0.69
0.209 0.71-
1.00
0.214 0.70-
0.98
rs4745122* 9 73582507 A Intergenic 0.351 5.48 × 10
-5 1.87 0.243 0.007 1.25 0.234 0.748 0.97 A 3.7 2.15
×
10
-4
++-
0.225 1.38-
2.54
0.205 1.06-
1.47
0.239 0.83-
1.14
rs7171137 15 90363631 A SLCO3A1 0.397 3.79 × 10
-5 1.84 0.370 0.013 1.20 0.351 0.620 1.04 A 4.1 4.09
×
10
-5
+++
0.264 1.38-
2.47
0.330 1.04-
1.38
0.343 0.90-
1.19
rs183211 17 42143493 T NSF 0.207 7.16 × 10
-5 0.54 0.213 0.102 0.87 0.196 0.001 0.77 T -5.1 2.80
×
10
-7
---
0.326 0.40-
0.73
0.236 0.75-
1.03
0.241 0.65-
0.90
rs415430 17 42214305 C WNT3 0.202 8.45 × 10
-5 0.54 0.173 0.002 0.77 C -5.0 6.87
×
10
-7
–
– 0.317 0.40-
0.74
0.214 0.65-
0.91
A1: Minor allele, A2: Associated allele, F_A: Minor allele freq. of case, F_U: Minor allele freq. of control, OR: odds ratios, 95% CI: 95% confidence interval, *
rs4745122 is located ~8.9Kb proximal to TMEM2.
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in two datasets.
NINDS and CIDR/PANKRATZ
In the NINDS Dataset, we re-examined the data set
and identified four SNPs that reached genome wide
significance at p < 9.7 × 10
-8 (Figure 2b, Additional file
2). Of the four SNPs, one SNP (rs3784847) was located
within a gene, CDH8, and the remaining three SNPs
were in intergenic regions. The allele frequencies were
low for these SNPs (< 10%). In the CIDR/Pankratz et
al 2009 dataset, we identified one SNP (rs2451078)
that reached genome-wide significance with p < 1.94 ×
10
-10 (Figure 2c, Additional file 2), and this SNP
(rs2451078) was located in an intron of the gene trans-
membrane phosphoinositide 3-phosphatase and tensin
homolog 2 (TPTE2). SNPs that reached genome wide
significance in the NINDS and CIDR/Pankratz et al
2009 datasets were not replicated in the AJ or a second
Figure 2 Manhattan plot for results of GWAS. a) Ashkenazi Jewish, b) NINDS and c) CIDR/Pankratz et al 2009. Manhattan plot of GWAS
results of testing for association with PD. Horizontal axis is the genomic position, and vertical axis is -log10 (p-value) in 3 datasets. Blue line
indicates the threshold of genome-wide significance level (Ashkenazi Jewish, p = 9.5×10
-8; NINDS, p = 9.7×10
-8; CIDR/Pankratz et al 2009, p =
1.5×10
-7).
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further.
SNP and Haplotype Analysis for Candidate Loci
LOC153328/SLC25A48 (5q31.1)
Rs4976493 in LOC153328/SLC25A48 was associated
with PD in the AJ and NINDS datasets, but not in the
CIDR/Pankratz et al 2009 dataset. However, the meta-
analysis based on the three datasets supported associa-
tion with PD (rs4976493, p = 0.005) (Table 2). We then
performed a 2-mer and 3-mer sliding window haplotype
analysis (Additional file 3a). Strongest association in the
AJ dataset was observed for a 2-mer haplotype
rs4976493- rs4246802 (’GG’)( A J :p=6 . 9 3×1 0
-5;
NINDS: p = 0.025) (Additional file 3a). In the NINDS
dataset, the haplotype involving rs2304075-rs6596270
‘TT’ was most significantly associated with PD (p =
0.008, with global-p = 0.027) and this haplotype was
also significant in the AJ dataset (p = 0.003, with global-
p = 0.004).
Figure 3 Regional Association Plots for SNPs significant in the association analysis in the Ashkenazi Jewish dataset a) NSF and WNT3,
b) LOC153228/SLC25A48,c )UNC13B,d )SLCO3A1. It shows -log10 (p-value) from association analysis for all SNPs in the region around the top
SNP (surrounding 1000 kb total). X-axis shows position of the SNPs along chromosome; Y-axis gives -log10(p-value). P-values were obtained from
GWAS in each dataset. Y-axis in the right shows recombination rate (cM/Mb). r
2 shows measure of the LD between this SNP and target SNP.
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rs10121009 was consistently associated with PD in all
three datasets (Table 2 meta analysis p = 2.75 × 10
-6)
and the direction of association was consistent across
studies. Our 2-mer and 3-mer sliding window haplotype
analysis identified strongest association for a 3-mer hap-
lotype ‘rs7040048- rs10121009- rs10114937 (’AAG’)( A J :
p = 5.09 × 10
-5; NINDS: p = 0.046; CIDR/Pankratz et al
2009: p = 0.035) (Additional file 3b) in each dataset.
SLCO3A1 (15q26.1)
Allele A in rs7171137 was consistently associated with
increased risk of PD in all the AJ and NINDS datasets
and the meta analysis supported the association (p =
4.09 × 10
-5, Table 2). Moreover, haplotype ‘GA’ at SNPs
rs2387400-rs7171137 was associated with PD (p = 4.04
×1 0
-5 in the AJ dataset and 0.014 in the NINDS data-
set) (Additional file 3c).
NSF (17q21.31) and WNT3 (17q21.32)
Because the two genes are closely located with each
other and with MAPT, we present each gene indepen-
dently first, then the region as a whole, including
MAPT. We observed a strong single and haplotype asso-
ciation between PD and rs183211 (NSF)i nt h eA Ja n d
CIDR/Pankratz et al 2009 datasets, but not in the
NINDS dataset (Figure 4a, b, c). In addition, WNT3,
located adjacent to NSF was also associated with PD in
the AJ and NINDS datasets (Figure 3a, Table 2 Addi-
tional file 3d). In comparison, rs1981997, a SNP with
the strongest support in MAPT,w a ss i m i l a r l y ,b u t
slightly weakly, associated with PD in the AJ dataset (p
= 0.0009) and the CIDR/PANKRATZ dataset (p =
0.0002).
Because NSF and WNT3 are closely located to MAPT
and multiple datasets show support for possible associa-
tion with PD, we examined this region encompassing
MAPT-NSF-WNT3 further. For this purpose, we used
the three most significant SNPs for each gene:
(rs183211) in NSF,o n e‘H1 TagSNP’ (rs1981997) in
MAPT, and rs415430 in WNT3.T h i sa n a l y s i si st o
determine whether the NSF and WNT3 SNP confer an
independent association or whether the association with
the NSF SNP was primarily due to high linkage disequi-
librium between the two SNPs. We reasoned that, if
there exist an independent contribution from NSF,
WNT3, or both, we expect to see allelic or haplotype
association in NSF, WNT3 or both, regardless of the
SNP allele at MAPT. However, this analysis is limited in
the present study, because the allele frequency of the ‘A’
allele is low in all three datasets (i.e., 0.216 in the AJ,
0.202 in the NINDS, and 0.202 in the CIDR/PANK-
RANTZ dataset). Table 3 supports that the C-T haplo-
type at NSF and WNT3 was associated with PD (p =
1.91 × 10
-5). When we extended the analysis to include
the 3-mer haplotypes by including the associated SNP at
MAPT, we observed that G-C-T haplotype was strongly
associated with PD as was the C-T haplotype at NSF
and WNT3 (p = 0.00014), but A-C-T was not (p =
0.1172). This suggests that LD may play a role in the
association with NSF and WNT3. However, haplotype
A-C-T frequency was higher in cases than in controls.
While haplotype A-C-T association was not statistically
significant, this association does support the possibility
that a variant(s) in the NSF and WNT3 may contribute
to PD, independent of MAPT. This association was
replicated in the NINDS dataset, but not in the CIDR/
PANKRATZ because the CIDR/PANKRATZ dataset
lacked the SNP in WNT3. Taken together, there is sug-
g e s t i v ee v i d e n c et h a tNSF and WNT3 are candidate
genes that need to be further studied.
LOC100505836 (3p24)
The SNP rs1694037, located in LOC100505836, was
replicated in the CIDR dataset (p = 0.049) but not in
the NINDS dataset (p = 0.849) and was not significant
in the meta-analysis of all three datasets (Table 2).
Intergenic SNP rs4745122 (Chr9q21.13)
The intergenic SNP, rs4745122, maps ~8.9kb proximal
to TMEM2. This SNP was replicated in the NINDS (p =
0.007) but not the CIDR dataset (p = 0.748) and was
significant in the meta analysis of all three datasets (p =
2.17 × 10
-4).
Replication of Previously identified PD Susceptibility
Genes
In the analysis of the discovery AJ dataset, the previously
identified PD susceptibility genes MAPT, SNCA, LRRK2,
G B A ,P A R K 1 6 ,B S T 1 ,H L A ,S Y T 1 1 ,A C M S D ,S T K 3 9 ,
LAMP3, GAK and CCDC6/HIP1R were not included in
the top 57 candidate SNPs/genes. GBA and LRRK2 were
reported in the AJ sample derived from PD EPI study
previously [22,30]. These genes also failed to reach gen-
ome wide significance in the NINDS and CIDR/Pankratz
et al 2009 datasets. As shown in previous studies, it is not
unexpected to miss risk genes in GWAS when SNP cov-
erage is sparse in the candidate gene regions. Thus we
further assessed association of SNPs at the chromosomal
regions harbouring these genes in the AJ dataset and per-
formed a meta-analysis including the NINDS and CIDR/
Pankratz et al 2009 datasets. PD susceptibility genes that
were associated in the AJ dataset are reported below.
MAPT (17q21.31)
We assessed associated SNPs and the presence of chro-
mosome 17q21.31 alleles in the H1-H2 haplotype clades
in MAPT using ‘rs1981997’ (HAPMAP CEU: ‘A’ = 0.208
and ‘G’ = 0.792) as a haplotype Tag SNP because the
major (G) allele and the minor (A) allele of this SNP are
fixed in the H1 and H2 clades respectively [31]. H1-H2
Liu et al. BMC Medical Genetics 2011, 12:104
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in the allelic and haplotype association analyses in both
AJ and CIDR/Pankratz et al 2009 datasets. As discussed
above, the present study supports the notion that in
addition to M A P T ,N S F ,W N T 3 , or both contribute to
PD susceptibility (Table 3).
SNCA (4q21)
In a recently published GWAS of PD in Caucasian sub-
jects, SNCA showed the strongest association of ‘top’
SNPs analyzed (SNCA intron, rs356220, p = 2.7 × 10
-6,
OR = 1.48; 95% CI [1.25-1.74]) [15]. A meta-analysis of
PD GWAS also confirmed the association (rs356219, p
Figure 4 Single point and haplotype analysis of MAPT-NSF region in a) Ashkenazi Jewish, b) NINDS and c) CIDR/Pankratz et al 2009
datasets. 2-SNP sliding window analysis the strongest p-value was present from the exhaustive search.
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-26). We assessed association of SNPs at the
SNCA locus in all three datasets (Additional file 4). The
SNP, rs11931074 (meta-analysis p value = 5.65 × 10
-5),
which maps near to SNCA was the most strongly asso-
ciated SNP in the meta-analysis (data not shown). The
same SNP (rs11931074) was also the most significantly
associated SNP (p =7 . 3 5×1 0
-17, OR = 1.37) in a
GWAS of PD in a Japanese population.
LRRK2 (12q12)
We assessed association of SNPs at the 12q12 region
harbouring the LRRK2 gene in each dataset. SNPs
within or near to LRRK2 did not reach genome wide
significance in any of the datasets and were not included
in the top ‘57’ SNPs in the AJ dataset. However, we gen-
otyped all subjects in the AJ dataset for the LRRK2
’G2019S’ mutation, and observed an association of hap-
lotypes consistent with previously published studies
[20,30]. Strongest association was observed for the hap-
lotype rs1427271-rs10735934-rs34637584 ‘GTA’ (p =
7.66 × 10
-5) (Additional file 4 for single point analysis;
haplotype results not shown).
GBA (1q21)
Although SNPs within the GBA gene from the GWAS did
not reach genome wide significance in any of the datasets
analyzed we did observe strong association of SNPs and
haplotypes at the GBA locus in our AJ dataset. When we
assessed association of 8 SNPs at Chromosome 1q21
spanning a 74.4kb region from TRIM46 (rs4971100) to
SCAMP3 (rs3180018) we observed that SNPs located in
GBA were significantly associated with disease (i.e.
rs2990245: OR = 1.39; p = 0.015) (Additional file 4). Using
the SNPs from GWAS along with the GBA N370S allele
(which was genotyped in all subjects), our 2-mer and 3-
mer sliding window haplotype analyses flanking the GBA
N370S allele revealed that a risk haplotype spanning
~12.5Kb of ‘ATG’ (GBA ’N370S’, rs2049805 and
rs1045253) was associated with PD in the AJ dataset (p =
8.19 × 10
-4) but not in the replication datasets (Figure 5).
We previously reported that the GBA ‘N370S’ mutation is
associated with PD [22].
PARK16 (1q32.1)
The PARK16 locus was previously identified as a sus-
ceptibility locus in a GWAS of PD in a Japanese popula-
tion (p = 1.52 × 10
-12) [13] and was also confirmed in a
meta-analysis of PD GWAS. This region encompasses
multiple genes; therefore, we assessed SNPs for associa-
tion for a region spanning ~170 Kb (203905087-
204074636 bp) at the PARK16 locus in all three datasets
(Figure 6). In the AJ dataset the most strongly associated
SNP, rs823114 (p = 6.12 × 10
-4) was located in an inter-
genic region proximal to NUCKS1. Our analysis con-
firmed the finding of Satake et al (2009) [13] in a
Japanese population in which they found that rs823114
( p=2 . 7×1 0
-34) was strongly associated with transcript
Table 3 MAPT-NSF and MAPT-WNT3 interaction in the Ashkenazi Jewish Dataset: Multivariate logistic regression*
MAPT NSF WNT3 Ashkenazi Jewish NINDS CIDR/Pankratz et al 2009
Single
point
rs1981997 rs183211 rs415430 P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI
A 0.0009118 0.58 0.42-0.90 0.07504 0.86 0.73-1.01 0.0001569 0.72 0.61-0.86
T 6.68 × 10
-5 0.54 0.40-0.73 0.1015 0.87 0.74-1.02 0.001375 0.77 0.65-0.90
C 8.59 × 10
-5 0.54 0.30-0.74 0.002397 0.77 0.65-0.91 N/A
2-mer rs1981997 rs183211 rs415430 P-value Freq.
Cases
Freq.
Controls
P-value Freq.
Cases
Freq.
Controls
P-value Freq.
Cases
Freq.
Controls
G C 0.00034 0.7743 0.6657 0.2634 0.7654 0.7491 0.0003 0.791 0.7386
A C 0.2118 0.0187 0.0084 0.1986 0.0217 0.0157 0.1059 0.0128 0.0198
G T 0.3211 0.0466 0.0618 0.2344 0.0444 0.0364 0.9238 0.0326 0.0332
A T 0.00016 0.1604 0.264 0.0214 0.1685 0.1989 0.0007 0.1636 0.2084
T C 0.00023 0.1559 0.2558 0.0145 0.1647 0.1967
CC0.2912 0.0456 0.0617 0.0191 0.0081 0.0169
T T 0.2408 0.0512 0.0701 0.2133 0.0482 0.0395
C T 1.91 × 10
-
5
0.7473 0.6125 0.0269 0.7790 0.7469 N/A
3-mer A T C 0.00018 0.156 0.2585 0.0133 0.1626 0.1951
GC C 0.3544 0.0445 0.0584 0.0134 0.0081 0.0175
G T T 0.2446 0.0450 0.0628 0.2758 0.0422 0.0350
A C T 0.1172 0.0194 0.0066 0.2187 0.0222 0.0163
G C T 0.00014 0.7351 0.6137 0.0518 0.7649 0.7361 N/A
*Adjusted for age and sex. Age refers to age at onset for affected individuals, and age at examination for unaffected individuals. OR: odds ratios, 95% CI: 95%
confidence interval; P-values for allelic/haplotype association; Single point shows the protective allele of each SNP; N/A, SNP rs415430 is not available in PD/CIDR
data.
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Page 10 of 16levels of NUCKS1 suggesting that this gene is a promis-
ing candidate for PARK16. However this SNP was not
associated with PD in the replication datasets. In addi-
tion, two SNPs (rs708730 and rs1891094) in SLC41A1
were modestly associated with PD in the AJ dataset and
NINDS dataset.
BST1 (4p15.32)
The BST1 gene was previously identified as a susceptibil-
ity gene in a GWAS of PD in a Japanese population [13]
and was also confirmed in a meta-analysis of PD GWAS.
On 4p15.32, four SNPs (rs11931532, rs12645693,
rs4698412 and rs4538475) reached p < 5 × 10
-7 in the
Figure 5 Association and haplotype analysis of GBA mutation (GBA N370S) and flanking SNPs in 3 datasets. a) Single point analysis plus
2 haplotype analyses: with vs. without the mutation in Ashkenazi Jewish. b) Single and haplotype analyses without mutation in NINDS. c) Single
and haplotype analyses without mutation in CIDR/Pankratz et al 2009. 2-SNP sliding window, the strongest p-value was present from the
exhaustive search.
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Page 11 of 16combined analysis (data not shown). These four SNPs
showed strong disease association with almost the same
significance levels (ranging from p = 3.94 × 10
-9 to p =
1.78 × 10
-8,a l lO R=1 . 2 4 ) ;a m o n gt h e m ,r s 4 5 3 8 4 7 5w a s
the most strongly associated. The four SNPs were located
from intron 8 to 4.1 kb downstream of BST1 (bone mar-
row stromal cell antigen). LD analysis revealed that the
four SNPs were correlated with r
2 > 0.78 and lie within a
15 kb LD block containing BST1 [13]. We assessed
association of the four BST1 SNPs reported by Satake et
al (2009) for association in all three datasets but none
were significant. However the intronic BST1 SNP,
rs12502586, was marginally associated with PD in the AJ
(p = 0.027) and NINDS datasets (p = 0.014) and
rs3213710 was strongly associated with PD in CIDR/
Pankratz et al 2009 dataset (p = 6.39 × 10
-4) (Additional
file 4). Haplotype analysis in all three datasets confirmed
the association with BST1.
Figure 6 Single point and haplotype analysis of PARK16 in Ashkenazi Jewish a), NINDS b) and CIDR/Pankratz et al 2009 c) datasets.2 -
SNP sliding window, the strongest p-value was present from the exhaustive search.
Liu et al. BMC Medical Genetics 2011, 12:104
http://www.biomedcentral.com/1471-2350/12/104
Page 12 of 16HLA (6p21.3)
The HLA region was recently identified as a susceptibil-
ity locus in a late-onset sporadic PD population from
North America [16]. We did not find evidence for asso-
ciation of SNPs at the HLA-DRA region with PD in AJ
dataset (Additional file 4).
STK39 (Chr2q23.4)
The SNP rs2102808, located in the candidate gene
STK39 was significant (p = 3.31 × 10
-11) in a meta-ana-
lysis of PD GWAS. We assessed association of SNPs at
the STK39 locus in the AJ dataset (Additional file 5).
Two intronic SNPs, rs3754775 and rs6740826, located
~11 kb apart showed the strongest evidence of associa-
tion in the AJ dataset (p = 0.005, OR = 2.12, 95%
CI:1.24-3.62).
MCCC1/LAMP3
The SNP, rs1171141, located in the gene region
MCCC1/LAMP3 was significant (p = 2.10 × 10
-8)i na
meta-analysis of PD GWAS. We assessed the association
of SNPs at MCCC1 and LAMP3. The SNP, rs12493050,
located in LAMP3,s h o w e dt h es t r o n g e s te v i d e n c eo f
association in the AJ dataset (p = 0.005, OR = 0.64, CI:
0.47-0.88) (Additional file 5).
Conclusions
This study identifies the candidate gene regions
LOC100505836, SLC25A48, UNC13B, SLCO3A1, WNT3,
and NSF as new candidates for PD using an AJ case-
control population as a discovery dataset and two other
large publicly available dataset as replication datasets. By
utilizing a relatively genetically homogeneous AJ popula-
tion and searching for variants that are rare (defined as
a MAF threshold of 2% or higher), we report additional
susceptibility variants for PD. In addition, we examined
the magnitude of association of previously reported PD
candidate genes including MAPT, SNCA, LRRK2, GBA,
PARK16, BST1, HLA, SYT11, ACMSD, STK39, MCCC1/
LAMP3, GAK and CCDC62/HIP1R in the AJ dataset
and found them to be comparable to several reports in
North American and European populations.
Of the new candidate genes that we identified in this
study, many represent interesting candidates for PD
based on function, as discussed below, and warrant
additional follow up in independent studies and different
PD populations. Functional studies suggest a role for
three of the genes that we identified (SLC25A48,
UNC13B, and NSF) in neuronal signalling and the dopa-
mine pathway. SLC25A48 is a member of the solute car-
rier family 25 proteins that function as transporters of a
large variety of molecules including ATP/ADP and
amino acids [32]. Characterized SLC25s localize to the
inner mitochondrial membrane and are also often
referred to as mitochondrial carriers or uncoupling pro-
teins (UCPs) [33]. SLC25A48 is highly expressed in the
central nervous system (CNS) including the hypothala-
mus, pituitary and brainstem and has been shown to be
important in healthy neurons for energy production and
to have a role in neuronal signalling [34]. Previous stu-
dies have suggested a role for mitochondrial UCPs in
PD, Alzheimer disease and amyotrophic lateral sclerosis
[32].
The SNP rs10121009, located in UNC13B (MUNC13)
was included in the top 57 SNPs in the AJ dataset and
also showed evidence of strong association in a meta-
analysis for all three datasets (p = 2.75 × 10
-6). Experi-
ments in C. elegans and mammalian cellular models sys-
tems suggest a role for the MUNC13 family of proteins
in the priming of synaptic and secretory vesicles in a
step just preceding fusion with the plasma membrane.
MUNC13 has been shown to control the release of both
neurotransmitters and neuropeptides from motorneur-
ons in the Caenorhabditis elegans (C.elegans) neuro-
muscular junction [35]. The lipids and proteins involved
in these networks are highly conserved between C. ele-
gans and mammals.
Because NSF and WNT3 are closely located to MAPT
and multiple datasets show support for possible associa-
tion with PD, we examined this region encompassing
MAPT-NSF-WNT3 further. Our data support the possi-
bility that a variant(s) in the NSF and WNT3 may con-
tribute to PD, independent of MAPT. This association
was replicated in the NINDS dataset, but not in the
CIDR/pankratz et al 2009 dataset because the CIDR/
Pankratz et al 2009 dataset lacked the associated SNP in
WNT3. Taken together and based on the function of
t h e s eg e n e s ,t h e r ei ss u g g e s t i v ee v i d e n c et h a tNSF and
WNT3 are candidate genes that need to be further stu-
died. The function of NSF in vesicular trafficking and
membrane fusion is well documented and the protein
h a sa l s ob e e ns h o w nt op l a yar o l ei nt h ef u s i o no f
synaptic vesicles in the presynaptic membrane during
neurotransmission and to interact with neurotransmis-
sion receptors at the postsynaptic side [36]. More recent
studies suggest an interaction between NSF and the
Dopamine D1 receptor (D1R) which is important for
the membrane localization of D1R [37]. D1R plays
important roles in regulating motor coordination, work-
ing memory, learning and reward and D1R dysfunction
is as associated with both psychiatric and neurological
disorders including PD [38]. WNT3 is a member of the
WNT gene family which encode secreted signaling pro-
teins that play a role in several developmental processes,
including embryonic and adult neurogenesis. Postnatal
neurogenesis has been observed in two brain regions:
t h es u b v e n t r i c u l a rz o n e( S V Z )o ft h el a t e r a lv e n t r i c l e
and the subgranular zone (SGZ) of the dentate gyrus in
the hippocampus, among vertebrates including human.
Genetic factors essential for neural development
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regions. Cell proliferation of neural progenitors in the
SVZ of PD patients and animal models has been shown
to be decreased and modulated by dopamine.
We also replicate association of several previously
identified PD genes and loci in our AJ population
including MAPT, SNCA, LRRK2, GBA, PARK16, BST1,
STK39 and LAMP3.B o t hLRRK2 and GBA represent
the most common risk factors in the AJ PD popula-
tion. In the AJ dataset, we observed a significant asso-
ciation for the LRRK2 ’G2019S’ mutation as well as for
a single haplotype, and these findings are consistent
with previously published studies. Among 268 PD
cases, 31 (11.6%) individuals carried the LRRK2
G2019S mutation, and their mean age at onset was
younger/similar to non-carriers (mean age at onset of
56.5 (SD = 11.1) vs. 60.3 (SD = 12.3), respectively).
The GBA ’N370S’ mutation is the most common allele
reported in AJ PD cases in several studies however a
risk haplotype supporting a founder effect has not
been previously reported. In our AJ PD dataset we
identified a risk haplotype of ‘ATG’ (GBA ’N370S’,
rs2049805 and rs1045253)(p = 8.19 × 10
-4)s p a n n i n g
~12.5 Kb suggesting that these individuals share a
common founder. Among 268 PD cases, 28 individuals
carried the GBA N370S mutation (10.4%), and their
mean age at onset was younger/similar to non-carriers
(mean age at onset of 57.4 (SD = 12.4) vs. 60.2 (SD =
12.1), respectively).
Our analysis of the PARK16 locus in our AJ dataset
confirms the finding of Satake et al (2009) [13] in a
Japanese population and suggests that NUCKS1 is a pro-
mising candidate for PARK16. More recently, Tucci et al
(2010) [39] analysed the coding regions of 3 candidate
genes (NUCKS1, RAB7L1,a n dSLC41A1)a tPARK16 in
a British cohort of 182 PD patients. Novel mutations
were identified in 1 PD patient in RAB7L1 (K157R) and
in another patient in SLC41A1 (A350 V). Follow-up stu-
dies including re-sequencing of the NUCKS1 gene and
other candidate genes at the PARK16 region are
warranted.
In summary, our GWAS study has identified candidate
gene regions for PD that are implicated in neuronal sig-
nalling and the dopamine pathway. Although the power
to detect genome-wide level significance in the AJ data-
set was low because of the small sample size we have
demonstrated the utility of this dataset in gene and SNP
discovery both by replication in dbGaP datasets with a
larger sample size combined with joint analyses and by
replicating association of previously identified PD sus-
ceptibility genes. Follow-up genotyping, replication stu-
dies and sequencing will be needed to confirm our
findings in future studies.
Additional material
Additional file 1: ’Top’ 57 SNPs with P value < 9.9 × 10
-5 identified
in the Ashkenazi Jewish PD GWAS. ‘Top’ 57 SNPs with P value < 9.9 ×
10
-5 identified in the Ashkenazi Jewish PD GWAS. OR: odds ratios, 95% CI:
95% confidence interval.
Additional file 2: SNPs reaching Genome Wide Significance in the
NINDS and CIDR/Pankratz et al 2009 datasets. SNPs reaching
Genome Wide Significance in the NINDS and CIDR/Pankratz et al 2009
datasets. OR: odds ratios, 95% CI: 95% confidence interval.
Additional file 3: Haplotype analysis of LOC15328/SLC25A48,
UNC13B, SLCO3A1, WNT3 in 2 or 3 datasets. a). Haplotype analysis
of LOC15328/SLC25A48 in 3 datasets. These haplotype results in
Additional file 3 a), b), c) and d) are further evaluation of the SNPs in
Table 2. *SNP 1, rs2304075; 2, rs6596270; 3, rs4976493; 4, rs4246802; 5,
rs7717673. b) Haplotype analysis of UNC13B in 3 datasets. *SNP 1,
rs7036061; 2, rs7040048; 3, rs10121009; 4, rs10114937; 5, rs10758303. c)
Haplotype analysis of SLCO3A1 in 3 datasets. *SNP 1, rs1400784; 2,
rs2387400; 3, rs7171137; 4, rs12913189; 5, rs6496888. d) Haplotype
analysis of WNT3 in Ashkenazi Jewish and NINDS. *SNP 1,
rs12325819; 2, rs199533; 3, rs415430; 4, rs2074404; 5, rs199494; rs415430 is
not on the CIDR/Pankratz et al 2009 dataset.
Additional file 4: Single SNP association of the genes reported in
other studies: GBA, BST1, SNCA, HLA-DRA and LRRK2. Single SNP
association of the genes reported in other studies: GBA, BST1, SNCA, HLA-
DRA and LRRK2. F_A: Minor allele freq. of case, F_U: Minor allele freq. of
control, OR: odds ratios, 95% CI: 95% confidence interval.
Additional file 5: Single SNP association of the genes reported by
the International Parkinson Disease Genomics Consortium: STK39,
MCCC1 and LAMP3. Single SNP association of the genes reported by the
International Parkinson Disease Genomics Consortium: STK39, MCCC1 and
LAMP3. OR: odds ratios, 95% CI: 95% confidence interval
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